{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:34:56Z","timestamp":1793313296510,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.phrs.2022.106524","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T03:54:05Z","timestamp":1666929245000},"page":"106524","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation"],"prefix":"10.1016","volume":"186","author":[{"given":"Go","family":"Anan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemitsu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.phrs.2022.106524_bib1","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2215\/CJN.11201016","article-title":"Effectiveness of treatment modalities on kidney stone recurrence","volume":"12","author":"Zisman","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106524_bib2","first-page":"e86","article-title":"Kidney stones: a global picture of prevalence, incidence, and associated risk factors","volume":"12","author":"Romero","year":"2010","journal-title":"Rev. Urol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.urology.2007.09.034","article-title":"Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005","volume":"71","author":"Yasui","year":"2008","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000052367","article-title":"Course of calcium stone disease without treatment. What can we expect?","volume":"37","author":"Strohmaier","year":"2000","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ucl.2018.12.011","article-title":"Assessing cost-effectiveness of new technologies in stone management","volume":"46","author":"Bayne","year":"2019","journal-title":"Urol. Clin. North Am."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2015.07.041","article-title":"EAU guidelines on interventional treatment for urolithiasis","volume":"69","author":"Turk","year":"2016","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106524_bib7","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/iju.14355","article-title":"One-surgeon basketing technique for stone extraction during flexible ureteroscopy for urolithiasis: a comparison between novice and expert surgeons","volume":"27","author":"Anan","year":"2020","journal-title":"Int J. Urol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","article-title":"Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug","volume":"11","author":"Idris","year":"2009","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","article-title":"The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose","volume":"93","author":"Kanai","year":"1994","journal-title":"J. Clin. Investig."},{"issue":"11","key":"10.1016\/j.phrs.2022.106524_bib10","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/dom.12962","article-title":"Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension","volume":"19","author":"Chilton","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"22","key":"10.1016\/j.phrs.2022.106524_bib11","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106524_bib12","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.3405","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"5","author":"Xu","year":"2017","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib13","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int."},{"issue":"15","key":"10.1016\/j.phrs.2022.106524_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"New Engl. J. Med"},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diabetes Vasc. Dis. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10557-017-6724-3","article-title":"The Effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on cardiometabolic profile; beyond the hypoglycaemic action","volume":"31","author":"Lioudaki","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106524_bib18","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","article-title":"SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism","volume":"146","author":"Santos-Gallego","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.phrs.2022.106524_bib19","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.122.060402","article-title":"Metabolomic profiling of the effects of dapagliflozin in heart failure with reduced ejection fraction: DEFINE-HF","volume":"146","author":"Selvaraj","year":"2022","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.phrs.2022.106524_bib20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"Requena-Ibanez","year":"2021","journal-title":"JACC Heart Fail."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102417","article-title":"Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial","volume":"16","author":"Requena-Ibanez","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"issue":"6","key":"10.1016\/j.phrs.2022.106524_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0006-291X(92)90669-C","article-title":"Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin","volume":"184","author":"Kohri","year":"1992","journal-title":"Biochem Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.phrs.2022.106524_bib24","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1359\/jbmr.080514","article-title":"Morphological conversion of calcium oxalate crystals into stones is regulated by osteopontin in mouse kidney","volume":"23","author":"Okada","year":"2008","journal-title":"J. Bone Min. Res."},{"issue":"6","key":"10.1016\/j.phrs.2022.106524_bib25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00240-012-0514-y","article-title":"Biomolecular mechanism of urinary stone formation involving osteopontin","volume":"40","author":"Kohri","year":"2012","journal-title":"Urol. Res."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.juro.2012.05.078","article-title":"Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations","volume":"189","author":"Khan","year":"2013","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/ijms21010093","article-title":"The impact of glycosylation of osteopontin on urinary stone formation","volume":"21","author":"Anan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib28","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.kint.2017.09.022","article-title":"The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury","volume":"93","author":"Anders","year":"2018","journal-title":"Kidney Int."},{"issue":"20","key":"10.1016\/j.phrs.2022.106524_bib29","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.3390\/ijms21207676","article-title":"Sodium-glucose co-transporter 2 inhibitors correct metabolic maladaptation of proximal tubular epithelial cells in high-glucose conditions","volume":"21","author":"Shirakawa","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106524_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107808","article-title":"Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials","volume":"155","author":"Cosentino","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"7","key":"10.1016\/j.phrs.2022.106524_bib31","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00125-021-05424-4","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis","volume":"64","author":"Kristensen","year":"2021","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbrc.2014.10.039","article-title":"Novel frame-shift mutation in Slc5a2 encoding SGLT2 in a strain of senescence-accelerated mouse SAMP10","volume":"454","author":"Unno","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib33","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0022-5347(05)64621-6","article-title":"Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis","volume":"168","author":"Khan","year":"2002","journal-title":"J. Urol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106524_bib34","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.juro.2008.07.024","article-title":"Atorvastatin inhibits renal crystal retention in a rat stone forming model","volume":"180","author":"Tsujihata","year":"2008","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00240-007-0082-8","article-title":"Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection","volume":"35","author":"Okada","year":"2007","journal-title":"Urol. Res."},{"issue":"10","key":"10.1016\/j.phrs.2022.106524_bib36","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/HJH.0000000000003191","article-title":"Inhibition of platelet-derived growth factor pathway suppresses tubulointerstitial injury in renal congestion","volume":"40","author":"Matsuki","year":"2022","journal-title":"J. Hypertens."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib37","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/s41598-017-01953-4","article-title":"Systematic evaluation for effects of urine pH on calcium oxalate crystallization, crystal-cell adhesion and internalization into renal tubular cells","volume":"7","author":"Manissorn","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib38","first-page":"375","article-title":"Overexpression of miR30c5p reduces cellular cytotoxicity and inhibits the formation of kidney stones through ATG5","volume":"45","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG - the \"diuretic hypothesis\"","volume":"30","author":"McMurray","year":"2016","journal-title":"J. Diabetes Complicat."},{"issue":"7","key":"10.1016\/j.phrs.2022.106524_bib40","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"issue":"17","key":"10.1016\/j.phrs.2022.106524_bib41","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.phrs.2022.106524_bib42","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib43","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-018-0385-5","article-title":"Empagliflozin induces transient diuresis without changing long-term overall fluid balance in japanese patients with type 2 diabetes","volume":"9","author":"Yasui","year":"2018","journal-title":"Diabetes Ther."},{"issue":"11","key":"10.1016\/j.phrs.2022.106524_bib44","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.phrs.2022.106524_bib45","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib46","first-page":"199","article-title":"Histologic study of the early events in oxalate induced intranephronic calculosis","volume":"17","author":"Khan","year":"1979","journal-title":"Investig. Urol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106524_bib47","doi-asserted-by":"crossref","first-page":"F1574","DOI":"10.1152\/ajprenal.00382.2013","article-title":"A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I","volume":"305","author":"Worcester","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib48","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.1038\/s41598-022-12086-8","article-title":"Protective effect of bee pollen in acute kidney injury, proteinuria, and crystalluria induced by ethylene glycol ingestion in rats","volume":"12","author":"Elghouizi","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib49","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1442-2042.2005.01038.x","article-title":"Study of a rat model for calcium oxalate crystal formation without severe renal damage in selected conditions","volume":"12","author":"Yamaguchi","year":"2005","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.phrs.2022.106524_bib50","doi-asserted-by":"crossref","unstructured":"J.R. Ehrenkranz, N.G. Lewis, C.R. Kahn, J. Roth, Phlorizin: a review. Diabetes Metab. Res. Rev., 21, 1, 2005, pp. 31\u201338.","DOI":"10.1002\/dmrr.532"},{"issue":"5","key":"10.1016\/j.phrs.2022.106524_bib51","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.199","article-title":"Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats","volume":"84","author":"Wang","year":"2013","journal-title":"Kidney Int."},{"issue":"12","key":"10.1016\/j.phrs.2022.106524_bib52","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1073\/pnas.0500607102","article-title":"On the utility of pooling biological samples in microarray experiments","volume":"102","author":"Kendziorski","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib53","article-title":"beta-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis","volume":"11","author":"Chen","year":"2022","journal-title":"J. Extra Vesicles"},{"issue":"8","key":"10.1016\/j.phrs.2022.106524_bib54","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/biomedicines9081006","article-title":"Both Full-length and protease-cleaved products of osteopontin are elevated in infectious diseases","volume":"9","author":"Hattori","year":"2021","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","article-title":"Na+-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity","volume":"149","author":"Freitas","year":"2008","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib56","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.diabres.2008.11.003","article-title":"Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats","volume":"83","author":"Tabatabai","year":"2009","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib57","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.phrs.2022.106524_bib58","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.3902","article-title":"Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis","volume":"21","author":"Lovisa","year":"2015","journal-title":"Nat. Med."},{"issue":"3\u20134","key":"10.1016\/j.phrs.2022.106524_bib59","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12079-009-0068-0","article-title":"The role of osteopontin in inflammatory processes","volume":"3","author":"Lund","year":"2009","journal-title":"J. Cell Commun. Signal"},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/CIRCRESAHA.107.160408","article-title":"Osteopontin expression is required for myofibroblast differentiation","volume":"102","author":"Lenga","year":"2008","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1113\/JP277002","article-title":"RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition","volume":"597","author":"Koszegi","year":"2019","journal-title":"J. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/1440-1681.12494","article-title":"Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy","volume":"43","author":"Yaghobian","year":"2016","journal-title":"Clin. Exp. Pharm. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059073","article-title":"Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial","volume":"12","author":"Schietzel","year":"2022","journal-title":"BMJ Open"},{"issue":"9","key":"10.1016\/j.phrs.2022.106524_bib64","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/15563650903344793","article-title":"Are calcium oxalate crystals involved in the mechanism of acute renal failure in ethylene glycol poisoning?","volume":"47","author":"McMartin","year":"2009","journal-title":"Clin. Toxicol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106524_bib65","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.physbeh.2008.06.010","article-title":"Preferences of 14 rat strains for 17 taste compounds","volume":"95","author":"Tordoff","year":"2008","journal-title":"Physiol. Behav."},{"issue":"6","key":"10.1016\/j.phrs.2022.106524_bib66","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1023\/A:1020884312053","article-title":"Food intake, water intake, and drinking spout side preference of 28 mouse strains","volume":"32","author":"Bachmanov","year":"2002","journal-title":"Behav. Genet."},{"issue":"5","key":"10.1016\/j.phrs.2022.106524_bib67","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106524_bib68","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes. Metab."},{"issue":"7","key":"10.1016\/j.phrs.2022.106524_bib69","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm. Drug Dispos."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib70","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2022.106524_bib71","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2022.106524_bib72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00240-010-0296-z","article-title":"Plaque and deposits in nine human stone diseases","volume":"38","author":"Coe","year":"2010","journal-title":"Urol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10157-004-0292-0","article-title":"Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies","volume":"8","author":"Khan","year":"2004","journal-title":"Clin. Exp. Nephrol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106524_bib74","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/ki.1995.222","article-title":"Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney","volume":"47","author":"Kleinman","year":"1995","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.ASN.0000040593.93815.9D","article-title":"Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules","volume":"14","author":"Wesson","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib76","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1442-2042.2002.00429.x","article-title":"Osteopontin regulates adhesion of calcium oxalate crystals to renal epithelial cells","volume":"9","author":"Yasui","year":"2002","journal-title":"Int J. Urol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib77","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000030363","article-title":"Interaction between osteopontin on madin darby canine kidney cell membrane and calcium oxalate crystal","volume":"62","author":"Yamate","year":"1999","journal-title":"Urol. Int."},{"issue":"7","key":"10.1016\/j.phrs.2022.106524_bib78","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.freeradbiomed.2012.01.005","article-title":"Mitochondrial permeability transition pore opening induces the initial process of renal calcium crystallization","volume":"52","author":"Niimi","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.phrs.2022.106524_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.566506","article-title":"Mitochondrial dysfunction and kidney stone disease","volume":"11","author":"Chaiyarit","year":"2020","journal-title":"Front Physiol."},{"key":"10.1016\/j.phrs.2022.106524_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.phrs.2022.106524_bib81","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s42255-020-0238-1","article-title":"Altered proximal tubular cell glucose metabolism during acute kidney injury is associated with mortality","volume":"2","author":"Legouis","year":"2020","journal-title":"Nat. Metab."},{"issue":"9","key":"10.1016\/j.phrs.2022.106524_bib82","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106524_bib83","doi-asserted-by":"crossref","first-page":"9555","DOI":"10.1038\/s41598-017-09352-5","article-title":"Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats","volume":"7","author":"Ansary","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.phrs.2022.106524_bib84","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106524_bib85","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/jcp.2004.019588","article-title":"ACP Best Practice No 181: chemical pathology clinical investigation and management of nephrolithiasis","volume":"58","author":"Reynolds","year":"2005","journal-title":"J. Clin. Pathol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822004704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:36:10Z","timestamp":1760913370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822004704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":85,"alternative-id":["S1043661822004704"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106524","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742412939.793596625","asserted-by":"object"}]},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106524"}}